All In Biotech

Drug Trial Radar · NCT00068003

Harvesting Cells for Experimental Cancer Treatments

Cell Harvest and Preparation for Surgery Branch Treatment Protocols

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

7,000

Planned (sponsor's estimate)

Start

Sep 8, 2003

Primary completion

Not stated

Sponsor

Sponsor type
NIH
First posted
Sep 4, 2003

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers. ...

Conditions

  • Melanoma
  • Gastrointestinal Cancer
  • Metastatic Cancer
  • Breast Cancer
  • Non-Small Cell Lung Cancer

Interventions

  • Anti-CD19 CAR PBLDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Generating anti-tumor patient lymphocytes ex vivoTime frame: Approximately 20 years
  2. To conduct genomic, proteomic, and immunologic research studiesTime frame: Approximately 20 years
  3. To obtain autologous blood, stem cells, and/or tumor tissue from patients currently with cancerTime frame: Approximately 20 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.